Sonographic prediction of twin birth weight discordance.

OBJECTIVE: To assess the accuracy of sonographic prediction of clinically significant twin birth weight discordance (25% or greater) and to determine whether this accuracy is affected by defined fetal and maternal variables. METHODS: Using an established database, we reviewed 338 twin gestations delivered over 10 years as a retrospective cohort. Estimation of fetal weight was calculated by applying the Hadlock formula using composite fetal biometry. Intertwin weight discordance was calculated as the difference in the estimated or actual twin weights (A-B) divided by the weight of the larger twin and was expressed as a percentage. Statistical evaluation included validity (sensitivity, specificity, and predictive values) and reliability assessment of ultrasonographic measurements (intraclass correlation coefficients). Multivariable analysis was performed. RESULTS: Of 338 twin gestations, 192 (57%) twin pairs met inclusion criteria. Sonographic prediction of actual intertwin birth weight discordance of 25% or greater had a sensitivity of 55%, specificity of 97%, positive predictive value of 82%, and negative predictive value of 91%. The reliability of estimating intertwin birth weight discordance by ultrasonography was moderately high (intraclass correlation coefficient =.700; 95% confidence interval [CI].620,.765). Multivariable analysis revealed no significant effects of individual maternal or fetal factors on the accuracy of ultrasonographic prediction of intertwin birth weight discordance. CONCLUSION: Sonographic prediction of actual intertwin birth weight discordance of 25% or greater within 16 days of delivery appears to be a valid and reliable method for clinical use. Predictive accuracy is independent of other identifiable maternal or fetal variables.

Adaptive control with feedback strategies for suramin dosing.

Suramin, a drug used in the treatment of parasitic diseases, is currently being evaluated in clinical trials as an antineoplastic agent. The use of therapeutic drug monitoring and adaptive control with feedback in clinical trials of suramin was initially motivated by an association between acute neurologic toxicity and plasma suramin concentrations in excess of 350 micrograms/ml. We have prospectively examined the performance of both two- and three-compartment population pharmacokinetic models in controlling plasma suramin concentrations and have found that a three-compartment model best describes this drug. No correlation was found between the clearance of suramin and creatinine clearance, as had been previously hypothesized. The low systemic clearance of suramin and the number of parameters required to describe the three-compartment model suggest the need for a bayesian approach to the estimation of individual pharmacokinetics.